AIM IMMUNOTECH INC (AIM)
US00901B1052 - Common Stock
Taking everything into account, AIM scores 2 out of 10 in our fundamental rating. AIM was compared to 564 industry peers in the Biotechnology industry. AIM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AIM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AIM has reported negative net income.
AIM had a negative operating cash flow in the past year.
AIM had negative earnings in each of the past 5 years.
AIM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AIM has a worse Return On Assets (-178.46%) than 89.30% of its industry peers.
The Return On Equity of AIM (-459.60%) is worse than 78.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -178.46% | ||
| ROE | -459.6% | ||
| ROIC | N/A |
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AIM (71.14%) is better than 84.31% of its industry peers.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AIM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AIM has more shares outstanding
AIM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -42.64, we must say that AIM is in the distress zone and has some risk of bankruptcy.
AIM's Altman-Z score of -42.64 is on the low side compared to the rest of the industry. AIM is outperformed by 93.40% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that AIM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, AIM is doing worse than 60.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -42.64 |
ROIC/WACCN/A
WACC10.8%
2.3 Liquidity
A Current Ratio of 1.17 indicates that AIM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.17, AIM is doing worse than 84.85% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that AIM should not have too much problems paying its short term obligations.
AIM has a Quick ratio of 1.17. This is amonst the worse of the industry: AIM underperforms 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.00%.
Looking at the last year, AIM shows a quite strong growth in Revenue. The Revenue has grown by 19.64% in the last year.
Measured over the past years, AIM shows a very negative growth in Revenue. The Revenue has been decreasing by -11.26% on average per year.
EPS 1Y (TTM)-45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)19.64%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%19.05%
3.2 Future
Based on estimates for the next years, AIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.16% on average per year.
The Revenue is expected to grow by 217.99% on average over the next years. This is a very strong growth
EPS Next Y43.33%
EPS Next 2Y14.45%
EPS Next 3Y7.26%
EPS Next 5Y11.16%
Revenue Next Year-4.46%
Revenue Next 2Y236.73%
Revenue Next 3Y189.77%
Revenue Next 5Y217.99%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.45%
EPS Next 3Y7.26%
5. Dividend
5.1 Amount
No dividends for AIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AIM IMMUNOTECH INC
NYSEARCA:AIM (11/4/2024, 8:04:00 PM)
After market: 0.2572 +0 (+0.12%)0.2569
0 (-1.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -178.46% | ||
| ROE | -459.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y43.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.64%
Revenue growth 3Y7.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y